Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group.

CG, Groth; L, Bäckman; JM, Morales; R, Calne; H, Kreis; P, Lang; JL, Touraine; K, Claesson; JM, Campistol; D, Durand; L, Wramner; C, Brattström; B, Charpentier

doi:10.1097/00007890-199904150-00017

Public

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group.

Shared by NobleBlocks on Apr 1, 1999 • 12:00 AM UTC

Authors:

Groth CG

Bäckman L

Morales JM

Abstract

Background Sirolimus (rapamycin) is a potent immunosuppressant with a mechanism of action different from cyclosporine (CsA) or tacrolimus.Methods In 11 European centers, first cadaveric renal allograft recipients were randomized to CsA (n=42) or sirolimus (n=41). Dosing of these agents was concentra...

Discussions